Open AccessImpact of Expressing Cells on Glycosylation and Glycan of the SARS-CoV-2 Spike Glycoprotein
Author(s) -
Yan Wang,
Zhen Wu,
Wenhua Hu,
Piliang Hao,
Shuang Yang
Publication year - 2021
Publication title -
acs omega
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.779
H-Index - 40
ISSN - 2470-1343
DOI - 10.1021/acsomega.1c01785
Subject(s) - glycoprotein , glycosylation , glycan , spike (software development) , coronavirus , neuraminidase , biology , receptor , hemagglutinin (influenza) , virus , virology , microbiology and biotechnology , covid-19 , biochemistry , medicine , disease , pathology , infectious disease (medical specialty) , management , economics
The spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the first point of contact for the virus to recognize and bind to host receptors, is the focus of biomedical research seeking to effectively prevent and treat coronavirus disease (COVID-19). The mass production of spike glycoproteins is usually carried out in different cell systems. Studies have been shown that different expression cell systems alter protein glycosylation of hemagglutinin and neuraminidase in the influenza virus. However, it is not clear whether the cellular system affects the spike protein glycosylation. In this work, we investigated the effect of an expression system on the glycosylation of the spike glycoprotein and its receptor-binding domain. We found that there are significant differences in the glycosylation and glycans attached at each glycosite of the spike glycoprotein obtained from different expression cells. Since glycosylation at the binding site and adjacent amino acids affects the interaction between the spike glycoprotein and the host cell receptor, we recognize that caution should be taken when selecting an expression system to develop inhibitors, antibodies, and vaccines.